CoreAge Rx vs SnagRx
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and SnagRx head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 65 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make SnagRx a bad call — it's best for readers who want compounded semaglutide and tirzepatide at a flat lifetime price. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | SnagRx | |
|---|---|---|
| Brief Score | 94/100 (A) | 65/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | $69/mo on the Summer Start discount (list $299); month-to-month, no contract, flat at every dose, compounded |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | $119/mo on the Summer Start discount (list $399); month-to-month, no contract, flat at every dose, compounded |
| Coverage | US only; restrictions by state, confirmed at intake | All 50 states plus Washington D.C. (per Terms) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Fallingprice falling |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
SnagRx: Headline cut since our last reading: semaglutide moved from $99/mo to $69/mo and tirzepatide from $149/mo to $119/mo, both under a "Summer Start Discount" against list prices of $299 and $399. The company publishes these as month-to-month rates with no contract and says the rate locks for life once started; a countdown timer beside them reads all zeros, so treat the urgency as decoration rather than a deadline.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.